Risks for HLA–DRB1 susceptible alleles in anticyclic citrullinated peptide autoantibody (anti-CCP) -positive and -negative rheumatoid arthritis (RA).

HLA–DRB1†No. CasesOR (95% CI)p††
Anti-CCP-positive RA (2n = 2840)
  *04:056753.61 (3.02–4.30)1.23 × 10−50
  *09:013691.85 (1.54–2.22)2.48 × 10−12
  *10:011203.33 (2.31–4.81)1.25 × 10−11
  *01:012521.99 (1.61–2.47)1.79 × 10−10
  *04:04614.10 (2.41–6.97)1.84 × 10−8
  *04:01534.41 (2.47–7.85)4.30 × 10−8
  *04:10452.87 (1.69–4.89)4.96 × 10−5
Anti-CCP-negative RA (2n = 450)
  *04:05732.24 (1.67–3.01)3.78 × 10−8
  *09:01561.57 (1.14–2.16)5.15 × 10−3

  • ↵† DRB1 alleles were sorted by the relative predispositional effects (RPE) method in RA patients and controls.

  • ↵†† Threshold values were calculated according to the procedure of Benjamini and Hochberg for controlling the Bonferroni method.